Deregulated transcription factors in the emerging cancer hallmarks

Hasan, Adria; Khan, Naushad Ahmad; Uddin, Shahab; Khan, Abdul Q.; Steinhoff, Martin

doi:10.1016/j.semcancer.2023.12.001

Cited by 8 publications

(1 citation statement)

References 342 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cancer development and progression are multifaceted processes that entail several steps and rely on the persistent expression/silencing or activation/inactivation of transcription factors to facilitate the malignant growth and survival of cancer cells [ 1 ]. Transcription factors are DNA-binding proteins that attach to specific promoter or enhancer DNA sequences to orchestrate gene transcription by physically interacting with RNA polymerase and transcriptional co-regulators, including co-activators and co-repressors.…”

Section: Introductionmentioning

confidence: 99%

P53 and Rb Aberrations in Small Cell Lung Cancer (SCLC): From Molecular Mechanisms to Therapeutic Modulation

Papavassiliou,

Sofianidi,

Gogou

et al. 2024

IJMS

View full text Add to dashboard Cite

The genes coding for the tumor suppressors p53 and retinoblastoma (Rb) are inactivated in the vast majority of small cell lung cancer (SCLC) tumors. Data support the notion that these two deleterious genetic events represent the initial steps in the development of SCLC, making them essential for a lung epithelial cell to progress toward the acquisition of a malignant phenotype. With the loss of TP53 and RB1, their broad tumor suppressive functions are eliminated and a normal cell is able to proliferate indefinitely, escape entering into cellular senescence, and evade death, no matter the damage it has experienced. Within this setting, lung epithelial cells accumulate further oncogenic mutations and are well on their way to becoming SCLC cells. Understanding the molecular mechanisms of these genetic lesions and their effects within lung epithelial cells is of paramount importance, in order to tackle this aggressive and deadly lung cancer. The present review summarizes the current knowledge on p53 and Rb aberrations, their biological significance, and their prospective therapeutic potential, highlighting completed and ongoing clinical trials with agents that target downstream pathways.

show abstract

Section: Introductionmentioning

confidence: 99%